MedTrace Logo

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

NCT04804553 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-20

No results posted yet for this study

Summary

The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.

Conditions

  • Active Juvenile Psoriatic Arthritis

Interventions

DRUG

Apremilast

Participants will receive apremilast orally.

DRUG

Placebo

Participants will receive the matching placebo orally.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-17
Primary Completion
2028-03-21
Completion
2028-12-29
FDA Drug
Yes

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Greece
  • Italy
  • Lithuania
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • South Africa
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04804553 on ClinicalTrials.gov